Core Insights - Corcept Therapeutics (CORT) reported quarterly earnings of $0.29 per share, exceeding the Zacks Consensus Estimate of $0.23 per share, but down from $0.32 per share a year ago, resulting in an earnings surprise of +26.09% [1] - The company posted revenues of $194.43 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.73%, compared to $163.8 million in the same quarter last year [2] - Corcept shares have increased approximately 38.7% year-to-date, significantly outperforming the S&P 500's gain of 8.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.38 on revenues of $242.34 million, and for the current fiscal year, it is $1.39 on revenues of $899.03 million [7] - The estimate revisions trend for Corcept was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Corcept belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - ARS Pharmaceuticals, Inc. is another company in the same industry, expected to report a quarterly loss of $0.41 per share, with revenues projected to be $15.12 million, reflecting a significant year-over-year increase [9]

Core Viewpoint - Exponent (EXPO) reported quarterly earnings of $0.52 per share, exceeding the Zacks Consensus Estimate of $0.48 per share, but down from $0.57 per share a year ago, indicating an earnings surprise of +8.33% [1][2] Financial Performance - The company achieved revenues of $132.87 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.38% and showing a slight increase from $132.43 million year-over-year [2] - Over the last four quarters, Exponent has consistently surpassed consensus EPS estimates four times and revenue estimates three times [2] Stock Performance - Exponent shares have declined approximately 22.8% since the beginning of the year, contrasting with the S&P 500's gain of 8.2% [3] - The current Zacks Rank for Exponent is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.51 on revenues of $133.65 million, while the estimate for the current fiscal year is $1.96 on revenues of $530.18 million [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which may influence future stock performance [6] Industry Context - The Consulting Services industry, to which Exponent belongs, is currently ranked in the top 20% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Company Performance - Zynex Inc. reported a quarterly loss of $0.32 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, and a significant decline from earnings of $0.04 per share a year ago, indicating an earnings surprise of -60.00% [1] - The company posted revenues of $22.29 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 17.44%, and a substantial decrease from year-ago revenues of $49.88 million [2] - Over the last four quarters, Zynex has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates during the same period [2] Stock Performance - Zynex shares have declined approximately 68.9% since the beginning of the year, contrasting sharply with the S&P 500's gain of 8.2% [3] - The current Zacks Rank for Zynex is 4 (Sell), indicating expectations for the stock to underperform the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $28.13 million, while for the current fiscal year, the estimate is -$0.81 on revenues of $110.3 million [7] - The outlook for the Medical - Products industry, to which Zynex belongs, is currently in the bottom 26% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Insights - Baxter International reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.60 per share, and down from $0.68 per share a year ago, representing an earnings surprise of -1.67% [1] - The company posted revenues of $2.81 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.28%, and down from $3.81 billion year-over-year [2] - Baxter has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.64 on revenues of $2.9 billion, and for the current fiscal year, it is $2.50 on revenues of $11.35 billion [7] - The estimate revisions trend for Baxter was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Products industry, to which Baxter belongs, is currently in the bottom 26% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]

Core Viewpoint - InterDigital (IDCC) reported quarterly earnings of $6.52 per share, significantly exceeding the Zacks Consensus Estimate of $3.36 per share, and showing an increase from $4.57 per share a year ago, resulting in an earnings surprise of +94.05% [1] Financial Performance - The company achieved revenues of $300.6 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 56.06%, compared to $223.49 million in the same quarter last year [2] - Over the last four quarters, InterDigital has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] Stock Performance - InterDigital shares have increased approximately 26.6% since the beginning of the year, outperforming the S&P 500's gain of 8.2% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimates at $2.15 for the coming quarter and $11.72 for the current fiscal year [4][7] - The estimate revisions trend for InterDigital was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Wireless Equipment industry, to which InterDigital belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting that the industry outlook could materially impact stock performance [8]

Group 1: Earnings Performance - CRA International (CRAI) reported quarterly earnings of $1.88 per share, exceeding the Zacks Consensus Estimate of $1.83 per share, and showing an increase from $1.83 per share a year ago, representing an earnings surprise of +2.73% [1] - The company posted revenues of $186.88 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.00%, and up from $171.44 million year-over-year [2] - CRA has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] Group 2: Stock Performance and Outlook - CRA shares have declined approximately 7.5% since the beginning of the year, contrasting with the S&P 500's gain of 8.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.84 on revenues of $177.55 million, and for the current fiscal year, it is $8.00 on revenues of $723.24 million [7] Group 3: Industry Context - The Consulting Services industry, to which CRA belongs, is currently ranked in the top 20% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for CRA is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Core Insights - MasterCard reported quarterly earnings of $4.15 per share, exceeding the Zacks Consensus Estimate of $4.05 per share, and up from $3.59 per share a year ago, representing an earnings surprise of +2.47% [1] - The company achieved revenues of $8.13 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.85%, and up from $6.96 billion year-over-year [2] - MasterCard has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Financial Performance - The earnings surprise for the previous quarter was +4.48%, with actual earnings of $3.73 per share compared to an expected $3.57 [1] - Year-to-date, MasterCard shares have increased by approximately 6.2%, while the S&P 500 has gained 8.2% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $4.16, with expected revenues of $8.28 billion, and for the current fiscal year, the EPS estimate is $16.04 on revenues of $32.02 billion [7] - The earnings outlook and estimate revisions will be crucial for determining the stock's future performance [4][5] Industry Context - The Financial Transaction Services industry, to which MasterCard belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of MasterCard's stock may be influenced by the overall outlook for the industry [8]

Vanda, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $52.59 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.38%. This compares to year-ago revenues of $50.47 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commenta ...

Core Viewpoint - Bristol Myers Squibb reported quarterly earnings of $1.46 per share, exceeding the Zacks Consensus Estimate of $1.07 per share, but down from $2.07 per share a year ago, indicating a significant earnings surprise of +36.45% [1][2] Financial Performance - The company achieved revenues of $12.27 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.67% and showing a slight increase from $12.2 billion in the same quarter last year [2] - Over the last four quarters, Bristol Myers has consistently exceeded consensus EPS estimates and revenue expectations [2] Stock Performance and Outlook - Bristol Myers shares have declined approximately 18.7% year-to-date, contrasting with the S&P 500's gain of 8.2% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $1.67 for the upcoming quarter and $6.28 for the current fiscal year [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, which may negatively impact stock performance [8] - The correlation between near-term stock movements and earnings estimate revisions is significant, suggesting that tracking these revisions can provide insights into stock performance [5]

Xylem (XYL) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.09 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +10.53%. A quarter ago, it was expected that this water and wastewater treatment company would post earnings of $0.95 per share when it actually produced earnings of $1.03, delivering a surprise of +8.42%. Over the last fou ...